Clinical Trial Update: Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating vorinostat (MK-0683) or placebo plus bortezomib in participants with multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Vorinostat (vorinostat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2021-04-30